Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC

Primary Objective and Endpoint To identify decrease in Ki-67 mRNA following treatment with
entinostat across TNBC breast cancers.

Secondary Objectives and Endpoints To identify messenger ribonucleic acid (mRNA) gene
expression changes following treatment with entinostat, across TNBC.

To evaluate changes in the proliferation signature by mRNA expression following treatment
with entinostat across TNBC.

To identify differential kinome activation before and after treatment with entinostat across
TNBC

To correlate mutation and/or copy number variations by whole exome sequencing (WES) with mRNA
gene expression changes and reduction of proliferation signature following treatment with
entinostat across TNBC.

To correlate protein lysine hyperacetylation in peripheral blood and tumor from pre- and
post-entinostat treated TNBCs.

To explore molecular subtype, Programmed death-ligand 1 (PD-L1) and other immune checkpoint
molecule expression, immune gene and innate anti-programed cell death-1 resistance (IPRES)
expression signatures and phenotypes of tumor-infiltrating lymphocytes, including delineation
of effector and regulatory T cells, and define T cell receptor (TCR) repertoire prior to and
following entinostat treatment in TNBCs. We will also explore mutation and copy number
variation status, and predicted major histocompatibility complex (MHC) class I neoantigen
burden.

To document safety of entinostat in patients with TNBC prior to their scheduled surgical
resection per National Cancer Institute - Common Terminology for Adverse Events (NCI-CTCAE
v4.0).

Inclusion Criteria:

- Is female, age ≥ 18 years of age.

- For Part 1: Has histologically confirmed newly diagnosed Stage I-IIIC invasive breast
cancer that is triple negative (ER/PR <1%, Her2 negative) and is scheduled to undergo
definitive surgery (either lumpectomy, mastectomy) and meets the criteria listed
below:

1. Scheduled for lumpectomy or mastectomy and not considered a candidate for
neoadjuvant systemic treatment

2. No prior or current therapy for breast cancer

3. Amenable to a baseline research breast biopsy

For Part 2: Has histologically confirmed newly diagnosed Stage I-IIIC invasive breast
cancer that is ER positive (+/- PR positive) and is scheduled to undergo definitive surgery
(either lumpectomy, mastectomy) and meets the criteria listed below:

- Scheduled for lumpectomy or mastectomy and not considered a candidate for neoadjuvant
systemic treatment b. No prior or current therapy for breast cancer c. Amenable to a
baseline research breast biopsy

- Must have sufficient time to receive two doses of entinostat 7 days apart or
exemestane for 8 consecutive days with or without entinostat prior to surgery.

- Has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.

- Demonstrates adequate organ function

- Has normal cardiac function based on an electrocardiogram (ECG) with no clinically
significant abnormalities or risks including any of the following:

- Current uncontrolled hypertension (systolic >150 mm Hg and/or diastolic >100
mmHg) or unstable angina

- History of serious cardiac arrhythmia requiring treatment (exceptions: atrial
fibrillation, paroxysmal supraventricular tachycardia)

- History of myocardial infarction within 6 months of day 1 of dosing

- History of congestive heart failure according to New York Heart Association
(NYHA) criteria.

- For women of childbearing potential: Has a negative serum pregnancy test at screening
within 72 hrs of receiving study treatment. In addition, female subjects must either:

1. agree to the use of an approved method of contraception (ie, two adequate barrier
methods throughout the study starting with the screening visit) and to continue
its use for the duration of the study treatment through 120 days after the last
dose of entinostat if a woman of child-bearing potential, or

2. has documented inability to become pregnant (e.g., hysterectomy, bilateral tubal
ligation or oophorectomy, or post-menopausal as defined as total cessation of
menses for ≥ 2 years). Documented hysterectomy or oophorectomy must be confirmed
with medical records of the actual procedure or confirmed by an ultrasound. Tubal
ligation must be confirmed with medical records of the actual procedure otherwise
the patient must be willing to use 2 adequate barrier methods throughout the
study.

- Is able to swallow and retain oral medication.

- As determined by the enrolling physician or protocol designee, ability of the subject
to understand and comply with study procedures for the entire length of the study.

Exclusion Criteria:

- Stage IV breast cancer.

- Has clinically significant a) abnormal laboratory or ECG findings, b) history of
myocardial infarction or arterial thromboembolic events within 6 months of screening
or c) unstable angina, d) New York Heart Association (NYHA) Class III or IV disease or
e) a corrected QT (QTc) interval > 470 msec.

- Medical history of uncontrolled hypertension (NCI CTCAE grade 3 or 4) or diabetes
mellitus.

- Known active central nervous system metastases and/or carcinomatous meningitis.

- Prior history of another cancer within the previous 5 years with the exception of
adequately treated basal cell carcinoma or cervical intraepithelial neoplasia,
cervical carcinoma in situ or melanoma in situ.

- Another known malignancy other than breast cancer that is progressing or requires
active treatment.

- Is pregnant or lactating, or is of child-bearing potential and not willing to use an
approved method of contraception.

- Has a concomitant medical condition that precludes adequate study treatment compliance
or assessment, such as bleeding disorders or any other medical condition that would
increase risks of additional core biopsy for biomarkers.

- Is currently receiving treatment with a medication on the prohibited medication list
for entinostat (See section 11.1 Appendix A and section 4.5).

- Has allergy to benzamides or inactive components of the study medication (entinostat).

- Inability to take oral medications (eg, impairment of gastrointestinal (GI) function
or GI disease that may significantly alter the absorption of oral medications such as
ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome,
or small bowel resection).

- Is participating in another therapeutic clinical trial or has received another
investigational agent within 30 days prior to informed consent.

- Known human immunodeficiency virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C
Virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection
which is allowed).

- Has acute or currently active/requiring anti-viral therapy, hepatic or biliary disease
(with the exception of patients with Gilbert's syndrome, asymptomatic gallstones, or
stable chronic liver disease per investigator assessment).

- Known psychiatric or substance abuse disorders that would interfere with cooperation
with the requirements of the study.

- Medical history of an autoimmune disease that requires ongoing steroid therapy for >
14 days.